FDA Panel Will Have To Weigh Pediatric Cancer Drug’s ‘Higher Level’ Of Uncertainty Against Rare, Devastating Disease
FDA’s Oncologic Drugs Advisory Committee will vote 4 October on whether DFMO improves event-free survival in high-risk neuroblastoma. • Source: Shutterstock 
